Camp4 Therapeutics Corporation (CAMP)

Camp4 Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	0.65	0.35	-
Revenue Growth (YoY)	86.29%	-	-
Cost of Revenue	38.82	40.62	34.1
Gross Profit	-38.17	-40.27	-34.1
Selling, General & Admin	14.92	11.61	10.23
Research & Development	-	-	0.68
Operating Expenses	14.92	11.61	10.91
Operating Income	-53.09	-51.88	-45
Interest Expense	-0.03	-0.03	-
Interest & Investment Income	1.33	2.81	0.9
Other Non Operating Income (Expenses)	-0.01	-0.19	-0.1
Pretax Income	-51.79	-49.29	-44.19
Net Income	-51.79	-49.29	-44.19
Net Income to Common	-51.79	-49.29	-44.19
Shares Outstanding (Basic)	5	0	0
Shares Outstanding (Diluted)	5	0	0
Shares Change (YoY)	1087.44%	26.47%	-
EPS (Basic)	-11.04	-124.79	-141.51
EPS (Diluted)	-11.04	-124.79	-141.51
Free Cash Flow	-46	-44.83	-42.57
Free Cash Flow Per Share	-9.81	-113.51	-136.31
Operating Margin	-8142.33%	-14822.57%	-
Profit Margin	-7943.40%	-14083.14%	-
Free Cash Flow Margin	-7055.67%	-12809.43%	-
EBITDA	-51.39	-50.2	-44.12
D&A For EBITDA	1.7	1.68	0.88
EBIT	-53.09	-51.88	-45

Updated Nov 21, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q